课题基金 / 基金详情

项目摘要

项目成果

EDWARD H. SCHUCHMAN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The overall goal of this research is to use our unique mouse models of Types A & B Niemann-Pick disease (NPD) to develop new therapies for this disorder and to uncover novel pathogenic mechanisms. Two aims are proposed. Aim 1: Preclinical Evaluation of Two New Therapies. In the first set of studies we will evaluate a novel enzyme enhancement approach using the heat shock protein, Hsp70. These experiments are based on a recent publication showing that Hsp70 enhanced residual ASM activity and reduced lysosomal pathology in cells from Type A and B NPD patients, a finding that has been supported by new in vivo data obtained since the previous submission. The second set of studies will continue our work aimed at improved delivery of ASM to the lung using ICAM-1. A "proof-of-principle" gene transfer experiment will be undertaken that will use AAV8 vectors to express ASM/ICAM-1 fusion proteins in the livers of NPD mice. Uptake and efficacy of the fusion enzymes in the lung and other clinically important organs will be studied. New in vivo data also has been obtained to demonstrate the feasibility of this approach. Aim 2: Investigation of Novel Pathogenic Mechanisms Leading to ERT-Related Liver Toxicity. Preclinical ERT studies in ASM knockout (ASMKO) mice have shown that administration of recombinant ASM at doses above 5 mg/Kg results in liver bleeding, the release of liver enzymes, and death. We have recently found that sphingosine, not sphingomyelin, is the major accumulating lipid in the livers of these mice, and hypothesize that sphingosine storage is responsible, at least in part, for the ERT-associated toxicity. We will determine the source of accumulating sphingosine by evaluating the expression of ceramidases, sphingosine kinases and sphingosine-1-phosphate lyase in the ASMKO mice, and breed these animals to mice lacking sphingosine kinase-1 to determine the effects on ERT- associated liver toxicity. These results should provide a mechanistic basis for the clinical observations in the mice, and also may lead to new strategies to overcome this toxicity.
期刊论文(11)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.ymgme.2016.12.008
发表时间: 2017-01
期刊: Molecular genetics and metabolism
影响因子: 3.8
作者: [Schuchman EH, Desnick RJ]
通讯作者: Desnick RJ
DOI: 10.1038/gim.2017.7
发表时间: 2017-09
期刊: Genetics in medicine : official journal of the American College of Medical Genetics
影响因子: --
作者: [McGovern MM, Dionisi-Vici C, Giugliani R, Hwu P, Lidove O, Lukacs Z, Eugen Mengel K, Mistry PK, Schuchman EH, Wasserstein MP]
通讯作者: Wasserstein MP
DOI: 10.1084/jem.20132451
发表时间: 2014-07-28
期刊: The Journal of experimental medicine
影响因子: --
作者: [Lee JK, Jin HK, Park MH, Kim BR, Lee PH, Nakauchi H, Carter JE, He X, Schuchman EH, Bae JS]
通讯作者: Bae JS
DOI: 10.1186/s13023-021-01779-4
发表时间: 2021-03-25
期刊: Orphanet journal of rare diseases
影响因子: 3.7
作者: [Schuchman EH, Ledesma MD, Simonaro CM]
通讯作者: Simonaro CM
9
    Endocannabinoid-Based Treatment for the Neurologic Niemann-Pick Diseases
    Acid Sphingomyelinase and Niemann-Pick Disease
    ACID CERAMIDASE, CERAMIDE & FARBER DISEASE
    ACID SPHINGOMYELINASE & NIEMANN-PICK DISEASE
    海外基金